BR112014010495A2 - composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo - Google Patents

composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo

Info

Publication number
BR112014010495A2
BR112014010495A2 BR112014010495A BR112014010495A BR112014010495A2 BR 112014010495 A2 BR112014010495 A2 BR 112014010495A2 BR 112014010495 A BR112014010495 A BR 112014010495A BR 112014010495 A BR112014010495 A BR 112014010495A BR 112014010495 A2 BR112014010495 A2 BR 112014010495A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
cyanonaphthalen
pyridin
thio
Prior art date
Application number
BR112014010495A
Other languages
English (en)
Portuguese (pt)
Inventor
D Quart Barry
Yeh Li-Tain
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of BR112014010495A2 publication Critical patent/BR112014010495A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014010495A 2011-11-03 2012-11-02 composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo BR112014010495A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555450P 2011-11-03 2011-11-03
US201261616363P 2012-03-27 2012-03-27
PCT/US2012/063415 WO2013067425A1 (en) 2011-11-03 2012-11-02 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same

Publications (1)

Publication Number Publication Date
BR112014010495A2 true BR112014010495A2 (pt) 2017-04-25

Family

ID=47178362

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010495A BR112014010495A2 (pt) 2011-11-03 2012-11-02 composto de piridina 3,4-di-substituído, métodos de uso e composições compreendendo o mesmo

Country Status (21)

Country Link
US (2) US10047050B2 (enExample)
EP (2) EP2776028B1 (enExample)
JP (1) JP6025853B2 (enExample)
KR (1) KR101988066B1 (enExample)
CN (2) CN104023723B (enExample)
AU (1) AU2012332154B2 (enExample)
BR (1) BR112014010495A2 (enExample)
CA (1) CA2852490A1 (enExample)
DK (1) DK2776028T3 (enExample)
EA (1) EA026101B1 (enExample)
ES (1) ES2704233T3 (enExample)
HU (1) HUE040625T2 (enExample)
IL (1) IL232105A (enExample)
MX (1) MX352904B (enExample)
MY (1) MY180138A (enExample)
PH (1) PH12014500997B1 (enExample)
PL (1) PL2776028T3 (enExample)
SG (1) SG11201402016PA (enExample)
UA (1) UA114304C2 (enExample)
WO (1) WO2013067425A1 (enExample)
ZA (1) ZA201402795B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CA2852490A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN104311452B (zh) * 2014-09-27 2016-01-06 张远强 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途
CN104292124B (zh) * 2014-09-27 2016-01-20 张远强 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途
WO2017028762A1 (zh) * 2015-08-14 2017-02-23 广东东阳光药业有限公司 一种萘环化合物的晶型
SG11201804100UA (en) * 2015-12-08 2018-06-28 Ardea Biosciences Inc Pharmaceutical composition comprising a potent inhibitor of urat1
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN114315705B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
DE122008000051I1 (de) 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
CA2105617A1 (en) 1992-09-10 1994-03-11 Yoshikazu Iwasawa Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
AU2001275085A1 (en) * 2000-06-01 2001-12-11 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
JP3824899B2 (ja) * 2001-09-21 2006-09-20 株式会社ヒューマンセルシステムズ 腎臓及び胎盤型尿酸トランスポーターとその遺伝子
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2006026356A2 (en) 2004-08-25 2006-03-09 Ardea Biosciences, Inc. S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070099970A1 (en) 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
US20090131384A1 (en) 2006-03-22 2009-05-21 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
MX2010011603A (es) * 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CN102186832B (zh) 2008-09-04 2014-04-02 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
JP2012527475A (ja) 2009-05-20 2012-11-08 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及び方法
US20110082120A1 (en) 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
WO2011085009A2 (en) 2010-01-08 2011-07-14 Ardea Biosciences, Inc. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
CA2794798C (en) * 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
CA2802407C (en) * 2010-06-15 2018-01-23 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
CA2852490A1 (en) 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels
SG11201804100UA (en) * 2015-12-08 2018-06-28 Ardea Biosciences Inc Pharmaceutical composition comprising a potent inhibitor of urat1

Also Published As

Publication number Publication date
AU2012332154B2 (en) 2016-11-17
KR101988066B1 (ko) 2019-09-27
NZ623857A (en) 2016-08-26
HUE040625T2 (hu) 2019-03-28
US20140256748A1 (en) 2014-09-11
ZA201402795B (en) 2019-09-25
HK1198929A1 (en) 2015-06-19
WO2013067425A1 (en) 2013-05-10
CN104023723A (zh) 2014-09-03
JP2014532726A (ja) 2014-12-08
MX352904B (es) 2017-12-13
DK2776028T3 (en) 2019-02-04
EP3501520A1 (en) 2019-06-26
US20190135756A1 (en) 2019-05-09
AU2012332154A1 (en) 2014-05-01
PL2776028T3 (pl) 2019-03-29
US10047050B2 (en) 2018-08-14
CN104023723B (zh) 2017-05-31
PH12014500997A1 (en) 2014-08-04
KR20140095078A (ko) 2014-07-31
EA201490795A1 (ru) 2014-09-30
PH12014500997B1 (en) 2014-08-04
EA026101B1 (ru) 2017-03-31
EP2776028B1 (en) 2018-10-17
CA2852490A1 (en) 2013-05-10
ES2704233T3 (es) 2019-03-15
IL232105A0 (en) 2014-05-28
IL232105A (en) 2017-05-29
SG11201402016PA (en) 2014-05-29
MX2014005343A (es) 2014-09-08
MY180138A (en) 2020-11-23
JP6025853B2 (ja) 2016-11-16
US10570095B2 (en) 2020-02-25
EP2776028A1 (en) 2014-09-17
CN106963761A (zh) 2017-07-21
UA114304C2 (uk) 2017-05-25

Similar Documents

Publication Publication Date Title
BR112012032028A2 (pt) compostos de tioacetato, composições e métodos de uso.
EA201490795A1 (ru) 3,4-дизамещенное пиридиновое соединение, способы применения и содержащие его композиции
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
BR112019000201A2 (pt) compostos e seu uso na redução dos níveis de ácido úrico
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
ATE530524T1 (de) Substituierte sulfonamid-derivate
EA201890641A3 (ru) Стимуляторы sgc
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
BR112013031402A2 (pt) derivados de hidantoína como inibidores de kv3
BR112015024671A2 (pt) derivados de ureia úteis como inibidores de quinase
BR112013027034A2 (pt) "composições farmacêuticas compreendendo enzimas digestivas e seu uso".
BR112015019412A2 (pt) inibidores de bace1
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
EA200970871A1 (ru) Новое терапевтическое применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина
BR112018012183A2 (pt) composição cosmética e seu uso, formulação cosmética
BR112012017994A2 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BR112014011805A2 (pt) morfolinilbenzotriazinas para uso em terapia de câncer
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
BR112017023076A2 (pt) derivados do ácido ciclopropanocarboxílico e seus usos farmacêuticos
BR112014009165A2 (pt) sal e uso médico
BR112014014869A2 (pt) derivados de sulfonilaminopirrolidinona, sua preparação e sua aplicação terapêutica
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112015007641A2 (pt) tratamento da doença de alzheimer branda e moderada
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: ARDEA BIOSCIENCES, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL